I'll give you a little background on M4K Pharma. Our company, as in the Newman foundation scenario, is wholly owned by a charity. You could conceive of scenarios in which you attract impact investors who are willing to balance returns with other socially minded objectives when they place an investment. This would all be dealt with in a shareholders agreement in which it's very clear that maximization of value is not the sole criterion by which performance is evaluated.
We're envisioning a division of labour between the development and clinical trials of the drug and the sales and marketing, which Dr. Edwards was talking about before. This new business model would, for lack of a better term, de-risk an asset to the point where it's commercially attractive at a lower price for an actual industry participant who is looking to maximize profits to take on. There would be a negotiation between the business development entity and the manufacturing-distribution entity around pricing. We would be handing over a fully de-risked asset to that company at that point, where we could say that there's a business case to be made for selling at that price because they haven't borne any of the research and development risk.